WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment (WATCH Tranfuse)

March 30, 2026 updated by: University of Oxford

Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with.

Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients.

The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL.

80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this.

Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions.

A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Participants will be patients who have been diagnosed with haematological malignancies (MDS, AML and myeloma)

Description

Inclusion Criteria:

  • Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS), myeloma and AML
  • Intention to undertake disease modifying treatment
  • Life expectancy ≥ 6 months
  • Able to complete quality of life questionnaires
  • Willing and able to provide informed consent for participation in the study
  • Willing to receive blood products as part of normal NHS care

Exclusion Criteria:

  • Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG ≥3)
  • Participants with known arrhythmias or other significant cardiological conductivity disorders
  • Patients with severe comorbidities
  • Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety of the patient or quality of the data
  • Hospitalised patients
  • Patients currently participating in another interventional clinical study
  • Patients with a pacemaker or implanted cardioverter defibrillator or any cardiac implanted device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MDS
Participants with MDS
Device: Axvitiy Ax3 accelorometer
Participants will wear the accelometer for 2 months
AML
Participants with AML
Device: Axvitiy Ax3 accelorometer
Participants will wear the accelometer for 2 months
Myeloma
Participants with myeloma
Device: Axvitiy Ax3 accelorometer
Participants will wear the accelometer for 2 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Activity Monitoring
Time Frame: 2 months
To collect QoL data and activity data during an observational study to understand QoL through 2 treatment cycles of treatment exploring correlations of QoL with both Haemoglobin (Hb) and activity data.
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Oxford

Investigators

  • Principal Investigator: Matthew H Poynton, MBBS, University of Oxford

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 17, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

March 30, 2026

First Submitted That Met QC Criteria

March 30, 2026

First Posted (Actual)

April 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 18950

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on MDS (Myelodysplastic Syndrome)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe